Between-hospital variation in biopsy indication for patients with newly diagnosed glioblastoma in the Dutch Quality Registry for Neurosurgery
Authors:
- Ilaria ViozziIVIlaria Viozzi
- Gerjon HanninkGHGerjon Hannink
- Hilko ArdonHAHilko Ardon
- Rutger K. BalversRBRutger K. Balvers
- Lisette BosscherLBLisette Bosscher
- Sarita van GeestSGSarita van Geest
- Vincent K. Y. HoVHVincent K. Y. Ho
- Koos HovingaKHKoos Hovinga
- Rishi Nandoe TewarieRTRishi Nandoe Tewarie
- Pierre A. RobePRPierre A. Robe
Open Access
- 6 February 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 172 (3) , 625-632
Abstract
Purpose: This registry-based study aims to examine the variation in biopsy and resection indications for glioblastoma patients across Dutch hospitals and to identify patient- and hospital-related factors associated with the surgical treatment. Methods: Data from all 7443 adults with first-time glioblastoma surgery at 12 hospitals were obtained from the prospective population-based Quality Registry Neurosurgery in the Netherlands between 2011 and 2021. Patients were stratified by either biopsy or resection. We analyzed variation in American Association of Anesthesiologist (ASA) classification, Karnofsky Performance Score (KPS), gender and age distribution between the different centers. Between-hospital variation in biopsy percentage was analyzed using a funnel plot. Logistic regression was used to identify associated patient- and hospital-related factors. Results: In total, 32% of the newly diagnosed glioblastoma patients underwent a biopsy, with wide variations between the different centers (23–56%). Patients-related variables such as higher age or ASA classification and lower KPS were significantly associated with the indication for biopsy. After correction for these factors, between-hospital variation persisted, with two institutes performing more biopsies than expected and one less than expected. Median overall survival was 12.5 months (95% CI 12.2–12.9) in the resection group and 5.6 months (95% CI 5.1–6) in the biopsy group, with wide variations between the different centers. Conclusion: A substantial between-hospital variation in biopsy percentages was found. Patient factors (age, ASA classification and KPS) but also hospital factors (such as academic setting) impact surgical decisions. Variation persisted also after correction for potential confounders, indicating that other factors play a role in decision-making.Keywords
This publication has 23 references indexed in Scilit:
- Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysisJournal of Neuro-Oncology, 2020
- Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro SurgeryJournal of Neuro-Oncology, 2019
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialThe Lancet, 2019
- Impact of removed tumor volume and location on patient outcome in glioblastomaJournal of Neuro-Oncology, 2017
- Association of the Extent of Resection With Survival in GlioblastomaJAMA Oncology, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Glioblastoma in England: 2007–2011European Journal of Cancer, 2015
- Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registriesCancer, 2011
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Funnel plots for comparing institutional performanceStatistics in Medicine, 2004